Si-Bone at 2025 Truist MedTech: Strategic Growth and Expansion

At the Truist Securities MedTech Conference, Si-Bone (SIBN) reported a 25% increase in worldwide revenue for Q1 2025, with U.S. revenue up 27%, and highlighted a record 1,400 active surgeons. CFO Anshul Maheshwari outlined the company's focus on expanding its sales force to 100 territories and launching new devices, including a third breakthrough product; however, the company anticipates a slight decrease in gross margins to around 78% for the full year 2025, with a long-term target of 76% to 77% due to procedure mix shifts and increased capacity investments.

Analysis

Si-Bone Inc. (NASDAQ:SIBN) presented a strong growth narrative at the 2025 Truist Securities MedTech Conference, reporting a 25% year-over-year increase in Q1 2025 worldwide revenue, with U.S. revenue climbing 27%. This performance was supported by a record 1,400 active surgeons, a 300 year-over-year increase, and a 45% rise in physicians performing multi-modality procedures, leading to 30% growth in same-store sales. While Q1 gross margins were robust at approximately 80%, an 80 basis point year-over-year improvement, the company guided for a full-year 2025 gross margin of around 78%, with a long-term target of 76-77%. This anticipated moderation is attributed to a shifting procedure mix towards degen and trauma cases which typically involve fewer implants, the initial higher costs associated with scaling new products like Granite 9.5 and iFuse Torque TNT, and investments in expanded surgical capacity and automation. Strategically, Si-Bone is focused on innovation with plans to launch a new device specifically for SI joint dysfunction in Q1 and a third breakthrough product, underscoring its commitment to R&D which accounts for 10-12% of revenue. The company aims to expand its sales force to 100 territories within the next 12 to 18 months to drive deeper penetration into significant target addressable markets, such as the $2.5 billion SI joint dysfunction market where it currently has less than 10% penetration. Notably, Si-Bone achieved its second consecutive quarter of adjusted EBITDA profitability, with Q1 revenue growth significantly outpacing OpEx growth (3x), demonstrating operating leverage which is expected to continue.

Key Decisions for Investors

• Investors should assess Si-Bone's ability to sustain its strong revenue growth trajectory, driven by new product adoption like Granite 9.5 and iFuse Torque TNT, and the planned sales force expansion into 100 territories.
• Careful monitoring of gross margin evolution is warranted, particularly how the guided decrease to 78% for FY2025 and 76-77% long-term materializes due to the outlined procedure mix shifts and investments, against the backdrop of current 80% levels.
• Consider the company's progress in achieving sustained adjusted EBITDA profitability and leveraging its operating model, especially in light of its significant market penetration opportunities and the upcoming launch of a third breakthrough device.